Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q4 2025 Earnings Call Transcript
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q4 2025 Earnings Call Transcript February 27, 2026Amneal Pharmaceuticals, Inc. misses on earnings expectations.
Amneal Pharmaceuticals Inc. (AMRX)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rubric Capital Management David Rosen | 12,334,941 | $155,420,257 | 1.86% | |
| 2. | Citadel Investment Group Ken Griffin | 6,175,737 | $77,814,286 | +8% | 0.01% |
| 3. | Millennium Management Israel Englander | 3,360,198 | $42,338,495 | +1% | 0.02% |
| 4. | D E Shaw D. E. Shaw | 2,661,854 | $33,539,360 | +71% | 0.02% |
| 5. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 2,447,516 | $30,838,702 | -43% | 1.02% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.21 | 50,000 | $210,500.00 | 258,784 | 2021-12-17 | Filing | |
| $4.25 | 50,000 | $212,500.00 | 512,566 | 2021-12-16 | Filing | |
| $4.13 | 100,000 | $413,000.00 | 462,566 | 2021-12-15 | Filing | |
| $4.25 | 50,000 | $212,500.00 | 512,566 | 2021-12-16 | Filing | |
| $4.13 | 100,000 | $413,000.00 | 462,566 | 2021-12-15 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.72 | 50,000 | $586,000.00 | 291,029 | 2025-11-17 | Filing | |
| $11.92 | 131,856 | $1,571,723.52 | 146,403 | 2025-11-12 | Filing | |
| $9.23 | 32,000 | $295,360.00 | 225,433 | 2025-08-27 | Filing | |
| $9.50 | 6,340 | $60,230.00 | 146,403 | 2025-08-25 | Filing | |
| $9.66 | 114,492 | $1,105,992.72 | 152,743 | 2025-08-22 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 17,907,815 | $225,638,469 | 0% | |
| 2. | 14,298,520 | $180,161,353 | 0% | |
| 3. | 12,328,767 | $155,342,464 | 5.78% | |
| 4. | 5,609,040 | $70,680,550 | 0.01% | |
| 5. | 4,818,099 | $60,708,057 | 0% |
News See All
Amneal Pharmaceuticals, Inc. (AMRX) Added to S&P SmallCap 600 Index, Boosting Investor Visibility
Separately, on January 29, Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) announced that it would be added to the S&P SmallCap 600 Index. It is a popular benchmark for U.S.
7 Cheap Pharmaceutical Stocks to Buy According to Hedge Funds
According to research, the U.S.
Truist Raises PT on Amneal Pharmaceuticals (AMRX) to $15 From $14
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is one of the best performing pharma stocks in 2025. On January 7, Truist raised the price target on Amneal Pharmaceuticals, Inc.
10 Best Performing Pharma Stocks in 2025
On January 8, Michael Yee, global head of biotech research at UBS, appeared on CNBC’s ‘Squawk on the Street’ to discuss his bullish outlook on biopharma stocks in 2026 and the pharma M&A outlook...
Piper Sandler Lifts Amneal Pharmaceuticals, Inc. (AMRX)'s Price Target To $13 Following Q3 Earnings Beat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is among the 13 Most Undervalued Stocks Under $20 to Buy.
13 Most Undervalued Stocks Under $20 to Buy
The Nasdaq Composite slumped 3% last week, while the S&P 500 index was down 1.8% with leading AI stocks losing over $820 billion in market capitalization, as concerns over overvaluation sparked a substantial...
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Q3 2025 Earnings Call Transcript
Anthony DiMeo: Good morning, and thank you for joining Amneal Pharmaceuticals' third quarter 2025 earnings call. Today we issued a press release reporting Q3 results.
Amneal Pharmaceuticals, Inc. (AMRX): A Bull Case Theory
We came across a bullish thesis on Amneal Pharmaceuticals, Inc. on Value investing subreddit by nknown10. In this article, we will summarize the bulls’ thesis on AMRX.
Amneal Pharmaceuticals, Inc. (AMRX) Files BLA for XOLAIR® Biosimilar, Targets Multi-Billion-Dollar Market
Amneal Pharmaceuticals, Inc.
Hedge Fund Resource Center